A Phase II Study of Neoadjuvant FOLFIRINOX
NCT02178709
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
48
Enrollment
OTHER
Sponsor class
Conditions
Resectable Pancreatic Ductal Adenocarcinoma
Interventions
DRUG:
FOLFIRINOX
Sponsor
Indiana University